41 results on '"Brown, David"'
Search Results
2. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors
3. Optimization of ketone-based P2Y12 receptor antagonists as antithrombotic agents: Pharmacodynamics and receptor kinetics considerations
4. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors
5. New phenstatin–fatty acid conjugates: Synthesis and evaluation
6. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction
7. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
8. The design, synthesis, and biological evaluation of PIM kinase inhibitors
9. Discovery of XL413, a potent and selective CDC7 inhibitor
10. Fragment based discovery of a novel and selective PI3 kinase inhibitor
11. Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; the identification of (2 R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor
12. Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs
13. The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs
14. The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: The first clinical candidate
15. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates
16. The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist
17. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs
18. Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system
19. The identification of β-hydroxy carboxylic acids as selective MMP-12 inhibitors
20. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[( trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4- b]pyrazin-2(1 H)-one
21. DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity
22. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ
23. Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with biaryl P4 motifs
24. Structure and property based design of factor Xa inhibitors: Biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs
25. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR
26. Erratum to “Discovery of XL413, a potent and selective CDC7 inhibitor” [Bioorg. Med. Chem. Lett. 22 (2012) 3727–3731]
27. Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; the identification of (2R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor
28. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
29. Corrigendum to “DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity” [Bioorg. Med. Chem. Lett. 19 (2009) 894]
30. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics
31. Selective and dual action orally active inhibitors of thrombin and factor Xa
32. Design of potent inhibitors of human β-secretase. Part 1
33. Design of potent inhibitors of human β-secretase. Part 2
34. Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs
35. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
36. Synthesis and evaluation of δ-Lactams (Piperazones) as elastase inhibitors
37. Replacements for lysine in l-seryl-l-lysyl dipeptide amide inhibitors of candida albicans myristoyl-CoA:protein N-myristoyltransferase
38. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction
39. The combinatorial synthesis of a 30,752-compound library: discovery of SAR around the endothelin antagonist, FR-139,317
40. Sildenafil (VIAGRA TM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction
41. Optimization of ketone-based P2Y12 receptor antagonists as antithrombotic agents: Pharmacodynamics and receptor kinetics considerations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.